

Receipt

COPY OF PAPERS  
ORIGINALLY FILED

Attorney's Docket No. 35800/243653 (5800-38A)

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Rosana Kapeller-Liebermann, et al.  
Appl. No.: 10/068,134  
Filed: 02/06/2002  
For: 22012, A NOVEL HUMAN CARBOXYPEPTIDASE

Confirmation No.: 8517  
Group Art Unit: 1642

May 8, 2002

Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

RECEIVED

TECH CENTER 800 2900

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

In reviewing the Filing Receipt for the above referenced application, Applicant notes that errors appear as noted on the enclosed copy of the Filing Receipt. The Attorney Docket Number should be 35800/243543(5800-38A). Applicant requests that a corrected Filing Receipt be issued.

Respectfully submitted,

Eric J. Kron  
Registration No. 45,941

Customer No. 00826  
ALSTON & BIRD LLP  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center, Washington, DC 20231, on May 8, 2002.

  
Nora C. Martinez



## UNITED STATES PATENT AND TRADEMARK OFFICE

COPY OF PAPERS  
ORIGINALLY FILEDPage 1 of 2  
Alston & Bird

APR 18 2002

EJK

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20503  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/068.134	02/06/2002	1642	776	35800/243655 (5800-38A) 243653	10	22	3

CONFIRMATION NO. 8517

## FILING RECEIPT



\*OC000000007858446\*

00826  
ALSTON & BIRD LLP  
BANK OF AMERICA PLAZA  
101 SOUTH TRYON STREET, SUITE 4000  
CHARLOTTE, NC 28280-4000

Date Mailed 04/12/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

## Applicant(s)

Rosana Kapeller-Libermann, Chestnut Hill, MA;  
Kyle J. MacBeth, Boston, MA;  
Mark Williamson, Saugus, MA.

RECEIVED

## Assignment For Published Patent Application

Millennium Pharmaceuticals, Inc.

TECH CENTER 1800 2900

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/345,469 06/30/1999 PAT 6,369,210

## Foreign Applications

If Required, Foreign Filing License Granted 04/12/2002

Projected Publication Date: 07/25/2002

Non-Publication Request: No

Early Publication Request: No

Title

ALSTON & BIRD  
RTA  
RECEIVED  
4/19/02DOCKETED  
BY [signature]  
4-18-02

22012, a novel human carboxypeptidase

**Preliminary Class**

536

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)), the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)), the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).